Elena Paccosi

Dr. Elena Paccosi

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2014 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
FCF Ciaffardini
F Ciaffardini
SNS Nicolai
S Nicolai
MCM Caputo
M Caputo
Giovanni CanuGiovanni Canu
Giovanni Canu
EPElena Paccosi
Elena Paccosi
LSLuca Proietti De Santis
Luca Proietti De Santis
Cockayne syndrome (CS) is a progressive developmental and neurodegenerative disorder resulting in premature death at childhood and cells derived from CS patients display DNA repair and transcriptional defects. CS is caused by mutations in csa and csb genes, and patients with csb mutation are more prevalent. A hallmark feature of CSB patients is neurodegeneration but the precise molecular cause for this defect remains enigmatic. Further, it is not clear whether the neurodegenerative condition is due to loss of CSB-mediated functions in adult neurogenesis. In this study, we examined the role of CSB in neurogenesis by using the human neural progenitor cells that have self-renewal and differentiation capabilities. In this model system, stable CSB knockdown dramatically reduced the differentiation potential of human neural progenitor cells revealing a key role for CSB in neurogenesis. Neurite outgrowth, a characteristic feature of differentiated neurons, was also greatly abolished in CSB-suppressed cells. In corroboration with this, expression of MAP2 (microtubule-associated protein 2), a crucial player in neuritogenesis, was also impaired in CSB-suppressed cells. Consistent with reduced MAP2 expression in CSB-depleted neural cells, tandem affinity purification and chromatin immunoprecipitation studies revealed a potential role for CSB in the assembly of transcription complex on MAP2 promoter. Altogether, our data led us to conclude that CSB has a crucial role in coordinated regulation of transcription and chromatin remodeling activities that are required during neurogenesis.

Verified
Journal Article
Open access
PDF file
EPElena Paccosi
Elena Paccosi
LSLuca Proietti De Santis
Luca Proietti De Santis
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, characterized by an initial and progressive loss of dopaminergic neurons of the substantia nigra pars compacta via a potentially substantial contribution from protein aggregates, the Lewy bodies, mainly composed of α-Synuclein among other factors. Distinguishing symptoms of PD are bradykinesia, muscular rigidity, unstable posture and gait, hypokinetic movement disorder and resting tremor. Currently, there is no cure for PD, and palliative treatments, such as Levodopa administration, are directed to relieve the motor symptoms but induce severe side effects over time. Therefore, there is an urgency for discovering new drugs in order to design more effective therapeutic approaches. The evidence of epigenetic alterations, such as the dysregulation of different miRNAs that may stimulate many aspects of PD pathogenesis, opened a new scenario in the research for a successful treatment. Along this line, a promising strategy for PD treatment comes from the potential exploitation of modified exosomes, which can be loaded with bioactive molecules, such as therapeutic compounds and RNAs, and can allow their delivery to the appropriate location in the brain, overcoming the blood–brain barrier. In this regard, the transfer of miRNAs within Mesenchymal stem cell (MSC)-derived exosomes has yet to demonstrate successful results both in vitro and in vivo. This review, besides providing a systematic overview of both the genetic and epigenetic basis of the disease, aims to explore the exosomes/miRNAs network and its clinical potential for PD treatment.

22 October 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
SPSilvia Proietti
Silvia Proietti
Gaia Salvatore FalconieriGaia Salvatore Falconieri
Gaia Salvatore Falconieri
LBLaura Bertini
Laura Bertini
IBIvan Baccelli
Ivan Baccelli
EPElena Paccosi
Elena Paccosi
CCCarla Caruso
Carla Caruso
Plant hormones play a central role in various physiological functions and in mediating defense responses against (a)biotic stresses. In response to primary metabolism alteration, plants can produce also small molecules such as methylglyoxal (MG), a cytotoxic aldehyde. MG is mostly detoxified by the combined actions of the enzymes glyoxalase I (GLYI) and glyoxalase II (GLYII) that make up the glyoxalase system. Recently, by a genome-wide association study performed in Arabidopsis, we identified GLYI4 as a novel player in the crosstalk between jasmonate (JA) and salicylic acid (SA) hormone pathways. Here, we investigated the impact of GLYI4 knock-down on MG scavenging and on JA pathway. In glyI4 mutant plants, we observed a general stress phenotype, characterized by compromised MG scavenging, accumulation of reactive oxygen species (ROS), stomatal closure, and reduced fitness. Accumulation of MG in glyI4 plants led to lower efficiency of the JA pathway, as highlighted by the increased susceptibility of the plants to the pathogenic fungus Plectospherella cucumerina. Moreover, MG accumulation brought about a localization of GLYI4 to the plasma membrane, while MeJA stimulus induced a translocation of the protein into the cytoplasmic compartment. Collectively, the results are consistent with the hypothesis that GLYI4 is a hub in the MG and JA pathways.

26 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SFSilvia Filippi
Silvia Filippi
EPElena Paccosi
Elena Paccosi
ABAlessio Balzerano
Alessio Balzerano
MFMargherita Ferretti
Margherita Ferretti
GPGiulia Poli
Giulia Poli
LSLuca Proietti De Santis
Luca Proietti De Santis
Breast cancer (BC) is the most common cancer with the highest frequency of death among women. BC is highly heterogenic at the genetic, biological, and clinical level. Despite the significant improvements in diagnosis and treatments of BC, the high rate of cancer recurrence and resistance to treatment remains a major challenge in clinical practice. This issue is particularly relevant in Triple-Negative Breast Cancer (TNBC) subtype, for which chemotherapy remains the main standard therapeutic approach. Here, we observed that BC cells, belonging to different subtypes, including the TNBC, display an increased expression of Cockayne Syndrome group A (CSA) protein, which is involved in multiple functions such as DNA repair, transcription, mitochondrial homeostasis, and cell division and that recently was found to confer cell robustness when it is up-regulated. We demonstrated that CSA ablation by AntiSense Oligonucleotides (ASOs) drastically impairs tumorigenicity of BC cells by hampering their survival and proliferative capabilities without damaging normal cells. Moreover, suppression of CSA dramatically sensitizes BC cells to platinum and taxane derivatives, which are commonly used for BC first-line therapy, even at very low doses not harmful to normal cells. Finally, CSA ablation restores drug sensitivity in oxaliplatin-resistant cells. Based on these results, we conclude that CSA might be a very attractive target for the development of more effective anticancer therapies.

16 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EPElena Paccosi
Elena Paccosi
FCFederico Costanzo
Federico Costanzo
MCMichele Costantino
Michele Costantino
ABAlessio Balzerano
Alessio Balzerano
LMLaura Monteonofrio
Laura Monteonofrio
LSLuca Proietti De Santis
Luca Proietti De Santis
Significance: Here, we demonstrate that CSA and CSB proteins, primarily defined as DNA repair factors, are part of a ubiquitin/proteasome degradation process during cytokinesis. Both CSA and CSB localize at the midbody, a transient structure located at the intercellular bridge, where they recruit a ubiquitination/proteasomal degradation complex for the degradation of PRC1, thus allowing the separation of the daughter cells. Defects in CSA or CSB result in perturbation of the abscission, leading to cytokinesis defects that might explain part of the Cockayne syndrome phenotypes. Our results enlighten the role played by CSA and CSB in a ubiquitin/proteasome degradation process involved not only in transcription and DNA repair, but also in cell division.

Verified
Journal Article
Open access
PDF file
EPElena Paccosi
Elena Paccosi
ABAlessio Balzerano
Alessio Balzerano
LSLuca Proietti De Santis
Luca Proietti De Santis
The serine/threonine kinase Akt modulates the functions of numerous substrates, many of them being involved in cell proliferation and growth, metabolism, angiogenesis, resistance to hypoxia and migration. Akt is frequently deregulated in many types of human cancers, its overexpression or abnormal activation being associated with the increased proliferation and survival of cancer cells. A promising avenue for turning off the functionality of Akt is to either interfere with the K63-linked ubiquitination that is necessary for Akt membrane recruitment and activation or increase the K48-linked polyubiquitination that aims to target Akt to the proteasome for its degradation. Recent evidence indicates that targeting the ubiquitin proteasome system is effective for certain cancer treatments. In this review, the functions and roles of Akt in human cancer will be discussed, with a main focus on molecules and compounds that target various elements of the ubiquitination processes that regulate the activation and inactivation of Akt. Moreover, their possible and attractive implications for cancer therapy will be discussed.